Molecular mass: 1,113.201 g/mol PubChem compound: 58031952
Pibrentasvir is a pan-genotypic inhibitor of HCV nonstructural protein 5A (NS5A), which is essential for viral RNA replication and virion assembly.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| J05AP | Antivirals for treatment of HCV infections | J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals |
Pibrentasvir is an active ingredient of these brands:
United States (US)
Australia (AU)
Austria (AT)
Brazil (BR)
Canada (CA)
Croatia (HR)
Cyprus (CY)
Estonia (EE)
Finland (FI)
France (FR)
Hong Kong (HK)
Ireland (IE)
Israel (IL)
Italy (IT)
Japan (JP)
Lithuania (LT)
Netherlands (NL)
New Zealand (NZ)
Poland (PL)
Romania (RO)
Singapore (SG)
Spain (ES)
Turkey (TR)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
